Table 1.
Patients with AMAN or AMSAN treated in our department between 2012 and 2017. Patient no. 6 was additionally treated with propionate.
| No. | Age (years) | Sex | Symptoms | First therapy | Second therapy | Worst mRS during disease course | mRS at discharge |
|---|---|---|---|---|---|---|---|
| 1 | 88 | F | severe tetraparesis and respiratory failure | 5 × 20 g IVIG | 5 × 500 mg methyl-prednisolone | 4 | 5 |
| 2 | 78 | M | rapidly progressive tetraparesis with respiratory failure and cranial nerve involvement | 5 × 30 g IVIG | 5 × PLEX | 5 | 5 |
| 3 | 71 | M | severe progressive tetraparesis with respiratory failure and vegetative involvement | 5 × 40 g IVIG | 6× PLEX | 5 | 5 |
| 4 | 19 | M | distal symmetric hypoesthesia of the extremities and paresis of dorsal flexion of the foot | 3 × 25 g IVIG | 2 | 2 | |
| 5 | 75 | F | progressive tetraparesis with cranial nerve involvement and vegetative involvement | 5 × 30 g IVIG | 6 × PLEX | 5 | 4 |
| 6 | 33 | M | distal symmetric tetraparesis | 5 × IVIG (dosage not documented) | 4 | 0 | |
AMAN, acute motor axonal neuropathy; AMSAN, acute motor and sensory axonal neuropathy; F, female; IVIG, intravenous immunoglobulin; M, male; mRs, modified Rankin scale; PLEX, plasma exchange.